New RNA-Based Treatments Using Antisense and Gene Editing to Target Skeletal Muscle
Updated
Abstract
Four antisense oligonucleotides have received FDA approval for treating Duchenne muscular dystrophy (DMD).
- RNA-based therapeutics can modify RNA processing or correct disease-causing genes in skeletal muscle disorders.
- Antisense oligonucleotides induce exon skipping to restore the reading frame for dystrophin production.
- Current treatments face challenges such as inefficient delivery to skeletal and cardiac muscle and the need for repeat administration.
- Next-generation approaches aim to improve cellular uptake and stability through conjugation with peptides or antibodies.
- CRISPR-based strategies, including base and prime editing, could offer one-time corrections but raise questions about safety and delivery.
Simplified
Funding
Competing interests
T.Y. is a cofounder and shareholder of OligomicsTx Inc., which aims to commercialize antisense technology. T.K. declares no commercial or financial relationships that could be construed as a potential conflict of interest.
PubMed